Physician profile
Daniel Hendricks
NPI 1134730385
$53,436.50
in general payments reported to CMS, 2019-2025
34 companies · $38K in 2025
The $38K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,406 · 2022: $3,184 · 2023: $3,615 · 2024: $7,496 · 2025: $38K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $21K · Food and Beverage: $18K · Travel and Lodging: $5,402 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,063 · Education: $667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $21,075.00 |
| Food and Beverage | $17,640.50 |
| Travel and Lodging | $5,402.08 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,063.00 |
| Education | $666.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $28,981.06 | 2023-2025 | Zoryve |
| Janssen Biotech, INC. | $6,146.96 | 2021-2025 | Tremfya |
| Abbvie INC. | $2,104.09 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,844.62 | 2021-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $1,658.90 | 2021-2025 | |
| Dermavant Sciences, INC. | $1,618.17 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $1,295.91 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| Amgen INC. | $1,121.72 | 2021-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $1,121.11 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Incyte Corporation | $985.67 | 2021-2025 | Opzelura |
| Genzyme Corporation | $926.78 | 2021-2025 | |
| Lilly USA, LLC | $777.08 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Leo Pharma INC. | $657.72 | 2022-2025 | Adbry, Anzupgo |
| Pfizer INC. | $615.77 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $601.71 | 2022-2024 | Tremfya |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $519.89 | 2022-2025 | Sotyktu |
| Botanix Sb INC | $468.49 | 2025 | Sofdra |
| Mayne Pharma Commercial LLC | $341.13 | 2022-2024 | |
| Revance Therapeutics, INC. | $328.41 | 2024-2025 | Daxxify, Daxi |
| Kowa Pharmaceuticals America, INC. | $300.00 | 2025 | Zoryve |
| Organon LLC | $276.77 | 2025 | Vtama, Hadlima |
| Ucb, INC. | $214.27 | 2021-2025 | Bimzelx, Cimzia |
| Journey Medical Corporation | $124.95 | 2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $94.74 | 2021-2025 | Cabtreo, Jublia, Arazlo |
| Verrica Pharmaceuticals INC. | $55.24 | 2024-2025 | Ycanth |
| Almirall LLC | $51.18 | 2021-2025 | Seysara |
| Genentech USA, INC. | $36.65 | 2021 | |
| Vyne Pharmaceuticals INC. | $35.54 | 2021 | |
| Mallinckrodt Hospital Products INC. | $35.33 | 2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.27 | 2022 | |
| Biofrontera INC. | $21.40 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Lnhc, INC | $19.52 | 2025 | Zelsuvmi |
| Organogenesis INC. | $14.33 | 2024 | |
| Allergan, INC. | $14.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Hendricks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.